ID | 118791 |
タイトル別表記 | Significant response of sunitinib for RCC
|
著者 |
Tada, Kouki
Tokushima University
|
キーワード | molecular-targeted therapy
nivolumab
renal cell carcinoma
sunitinib
|
資料タイプ |
学術雑誌論文
|
抄録 | Introduction: A case of multiple liver metastases of clear cell RCC with a significant response to sunitinib as the fifth line after nivolumab is reported.
Case presentation: The patient was a 65-year-old man who underwent open nephrectomy for RCC. After the nephrectomy, he had recurrences several times, and metastasectomy had been performed for each recurrence. At 13 years after the nephrectomy, multiple liver, and lung metastases appeared. The treatment was switched to axitinib, followed by cabozantinib, then nivolumab. The best response was PR, SD, and PD for these three drugs, and treatment duration was 14, 3, and 3 months, respectively. As the fifth line, sunitinib was administered, with significant shrinkage of the multiple liver metastases, and PR has been maintained for 34 months. Conclusion: Sunitinib after an IO-drug showed a significant effect in spite of only slight efficacy with other VEGFR-TKIs, which may have occurred through the alteration of the immunological microenvironment. |
掲載誌名 |
IJU Case Reports
|
ISSN | 2577171X
|
出版者 | Japanese Cancer Association|John Wiley & Sons
|
巻 | 6
|
号 | 1
|
開始ページ | 41
|
終了ページ | 44
|
発行日 | 2022-10-18
|
権利情報 | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
病院
医学系
|